期刊文献+

曲伏前列腺素对降低青光眼眼压的临床观察

下载PDF
导出
摘要 青光眼是一个终身的慢性眼病,也是一种可预防的致盲性疾病。对于青光眼的治疗,目前,眼压是最确切可控制的危险因素;同时,眼压控制后多数青光眼病人视神经损害的发展得到减缓,也反证了高眼压的危害性。所有青光眼干预治疗的目标还是降低眼压,最终达到个体化的靶眼压。
作者 赵红霞
出处 《云南医药》 CAS 2007年第4期386-387,共2页 Medicine and Pharmacy of Yunnan
  • 相关文献

参考文献3

二级参考文献21

  • 1方敏,余敏斌.高眼压症认识新进展[J].国外医学(眼科学分册),2004,28(5):312-316. 被引量:22
  • 2葛坚.我国近五年青光眼临床与基础研究进展[J].中华眼科杂志,2005,41(8):710-716. 被引量:150
  • 3周文炳,主编.临床青光眼.北京:人民卫生出版社,1998.337-362.
  • 4Michaud JE,Friren B.Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.Am J Ophthalmol,2001,132:235-243.
  • 5Netland PA,Landry T,Sullivan EK,et al.Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol,2001,132:472-484.
  • 6Richard KP.A comparison of latanoprost,bimatoprost and travoprost in patients with elevated intraocular pressure:a 12-week,randomized,masked-evaluator multicenter study.Am J Ophthalmol,2004,137:387-388.
  • 7Leske MC,Heijl A,Hyman L,et al.Early manifest glaucoma trial:design and baseline data.Ophthalmology,1999,106:2144-2153.
  • 8Leske MC,Heijl A,Hussein M,et al.Factors for glaucoma progression and the effect of treatment:the early manifest glaucoma trial.Arch Ophthalmol,2003,121:48-56.
  • 9Leskea MC,Heijl A,Hyman L,et al.Factors for progression and glaucoma treatment:the early manifest glaucoma trial.Curr Opin Ophthalmol,2004,15:102-106.
  • 10AGIS Investigators.The advanced glaucoma intervention study (AGIS):7.the relationship between control of intraocular pressure and visual field deterioration.Am J Ophthalmol,2000,130:429-440.

共引文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部